Eng

Forlax

Quick links to important sections

Forlax

Selected form

Macrogol

Method of action: Laxative

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Forlax

Forlax is a medicinal product used for the symptomatic treatment of chronic functional constipation in adults and children over the age of eight. It works by addressing the underlying issue of hard, dry stool by increasing the water content in the bowel.

Quick Facts

Property	Description
Active Ingredient	Macrogol 4000 (Polyethylene Glycol 4000)
Form	Powder for oral solution (sachets)
Pharmacological Class	Osmotic laxative
Common Use	Symptomatic relief of chronic constipation
Origin	Synthetic polymer

What Type of Medicine is Forlax? (Class, Composition, and Origin)

Forlax is classified as an osmotic laxative, a pharmacologic group that relies on a physical mechanism to function rather than stimulating the intestinal muscles. The active ingredient is Macrogol 4000, which is the International Nonproprietary Name (INN) for a specific form of Polyethylene Glycol (PEG 4000). This is a synthetic polymer with a mean molecular weight of 4000 Da. The use of Macrogol 4000 is established in managing chronic constipation and it is recognized as a standard treatment option. This inert, high-molecular-weight polymer is not absorbed into the bloodstream or broken down by digestive processes; its action is localized entirely within the gastrointestinal lumen.

What is the Purpose and Form of Forlax?

The general purpose of Forlax is to provide relief from the symptoms of sluggish bowel movements by softening and increasing the volume of stool to facilitate easier passage. Forlax is a specialized formulation of Macrogol 4000 often available with flavoring options and is used in both adults and children aged eight and older. It is supplied as a powder for oral solution, typically packaged in single-dose sachets that must be dissolved in a liquid before ingestion. This delivery form is essential because Macrogol 4000 binds to the dissolved water, creating an osmotic effect that prevents the reabsorption of fluid from the colon. This process helps restore intestinal motility by rehydrating the contents of the bowel.

What side effects are possible with Forlax?

Possible Side Effects and Safety Information

The safety profile of Macrogol 4000 (Forlax) is primarily defined by effects localized to the gastrointestinal system, consistent with its non-absorbed, osmotic mechanism of action. The frequency of documented adverse reactions is classified according to regulatory standards, with the majority of events being common and dose-related.

Official Adverse Reactions by Frequency

Classification	System-Organ Class	Examples from Regulatory Labels
Common (ge 1/100 to < 1/10)	Gastrointestinal Disorders	Abdominal pain and distension, diarrhoea, nausea.
Uncommon (ge 1/1,000 to < 1/100)	Gastrointestinal Disorders	Vomiting, urgency to defaecate, faecal incontinence.
Very Rare (< 1/10,000)	Immune System / Skin	Anaphylactic shock, angioedema (severe swelling), rash, urticaria (hives), pruritus (itching).

Serious Safety Considerations

The most serious reactions documented are severe hypersensitivity reactions, such as anaphylactic shock and angioedema, which have been reported in isolated cases via post-marketing surveillance. The risk of electrolyte disturbances (e.g., hyponatremia, hypokalemia) and associated dehydration is noted, particularly when the medicine is misused, taken in overdose, or used by patients with existing risk factors.

Population-Specific Safety Notes

The official prescribing information identifies cohorts with a potentially increased safety risk. Older adults, as well as patients with impaired renal or hepatic function, are noted to have a higher potential for developing electrolyte disturbances if high doses are administered. Additionally, the label documents the specific safety risk of aspiration for neurologically impaired children when the product is administered in large volumes via a nasogastric tube.

Restrictions and Limitations

Use of this medicine is restricted by contraindications that prohibit its use in individuals with underlying severe gastrointestinal conditions, including severe inflammatory bowel disease (e.g., ulcerative colitis, toxic megacolon), intestinal obstruction or symptomatic stenosis, digestive perforation or risk of perforation, and painful abdominal conditions of unknown cause. Regulatory documents also note that Macrogol 4000 may cause a transient reduction in the absorption of other medicinal products if taken at the same time.

Overdose and Emergency Response

Overdose Manifestations and Complications

Overdose of Forlax (Macrogol 4000) is primarily associated with an exaggeration of its osmotic action. Documented manifestations include severe gastrointestinal symptoms such as diarrhoea, abdominal pain, and vomiting. These effects typically resolve upon a temporary interruption of the product or a reduction in the dosage. The most critical documented risk is the potential for excessive fluid loss, which may lead to systemic electrolyte disturbances. Massive ingestion has been associated with metabolic anion-gap acidosis.

Required Emergency Action

Official regulatory guidance requires that patients seek immediate medical help or contact a Poison Control Center right away if an overdose is suspected. Management is symptomatic and supportive, focusing on the correction of electrolyte disturbances resulting from fluid loss. It is officially noted that no specific antidote is known for Macrogol 4000.

Population-Specific Risks

Population-specific considerations highlight that elderly patients or those with impaired hepatic or renal function are at increased risk of complications from fluid loss. Furthermore, the risk of pulmonary aspiration is specifically noted for neurologically impaired children with oromotor dysfunction.

Therapeutic Uses of Forlax

What Forlax Treats: Main Uses and Benefits

Forlax is commonly used to help with symptomatic relief across key therapeutic domains related to digestive discomfort. It plays a role in managing symptoms and helps ease the overall symptom burden associated with difficult or infrequent bowel movements, supporting a more comfortable experience during periods of strain. The active substance in Forlax is relevant for use in the symptomatic management of constipation and may be applied in addressing faecal impaction (a build-up of hard stool).

Easing Persistent and Acute Symptom Manifestations

This medication is relevant for managing symptom clusters that may become intense or disruptive in long-term (chronic) constipation. It is also commonly used when symptoms intensify during acute, challenging manifestations of the condition, where short-term supportive relief is needed. It offers a supportive benefit that helps patients cope more steadily with symptom fluctuations and assists with maintaining functional stability.

Quick Fact: Relief for Straining

Forlax may assist with managing the symptoms related to physical discomfort and noticeable physiological strain during bowel movements.

Eligibility and Restrictions for Use

Forlax (Macrogol 4000) is eligible for use in adults and children aged 8 years and above. Treatment for children should generally not exceed 3 months due to limited clinical data on longer-term use.

Populations Who Must Not Use Forlax (Contraindicated)

Use of Forlax is strictly contraindicated if the patient has:

Hypersensitivity (allergy) to macrogol (polyethylene glycol) or any of the excipients.
Severe inflammatory bowel disease (such as ulcerative colitis or Crohn’s disease).
Toxic megacolon associated with symptomatic stenosis.
Digestive perforation or an elevated risk of perforation.
Ileus or suspicion of intestinal obstruction.
Painful abdominal syndromes of indeterminate cause (the cause must be known and ruled out).

Populations Requiring Special Consideration

Use is not recommended for patients with hereditary fructose intolerance due to the potential presence of excipients like sorbitol or sulphur dioxide. Sulphur dioxide may also rarely cause severe hypersensitivity reactions.

Caution is advised for the elderly, or patients with impaired renal or hepatic function, or those taking diuretics. These groups are at a higher risk of water-electrolyte imbalance, which requires monitoring if diarrhea occurs. Special caution is also needed for patients with an impaired gag reflex or those prone to aspiration.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Forlax (macrogol 4000/polyethylene glycol) has a local, non-systemic mechanism of action in the gut, which primarily affects how other orally administered products are absorbed.

Interactions with Oral Medications

There is a possibility that the osmotic effect and increased intestinal transit caused by Forlax could transiently reduce the absorption and therefore the efficacy of other oral medications. This potential interaction is considered most clinically significant for products with a narrow therapeutic index (where small changes in concentration can have a large impact) or a short half-life.

Specific examples of medicines that may be affected include:

Digoxin
Anti-epileptic medicines (e.g., certain anticonvulsants)
Coumarins (a class of anticoagulants)
Immunosuppressive agents

To minimize this potential effect, it is generally recommended to administer Forlax at least two hours apart from other oral medicinal products.

Interaction with Starch-Based Food Thickeners

Forlax should not be mixed with liquids thickened with starch-based food thickeners. The polyethylene glycol (PEG) ingredient can counteract the thickening effect of starch, leading to the liquefaction of the preparation. This interaction is particularly important for patients with swallowing difficulties, as the resulting thinner liquid may increase the risk of aspiration.

Mechanism of Action

Macrogol 4000: Mechanism of Localized Osmotic Action

The mechanism of Forlax (Macrogol 4000) is entirely physico-chemical, operating solely within the gastrointestinal lumen without interacting with classical biological targets such as receptors, enzymes, or ion channels. The inert polymer functions as a non-absorbable solute that engages in hydrogen bonding with intestinal water molecules.

This molecular interaction generates a significant osmotic pressure gradient across the colonic mucosa, altering the physiological process of water reabsorption by limiting the net movement of fluid from the bowel back into the circulation. This causes a substantial increase in the stool's volume and a reduction in its mechanical resistance (softening).

The secondary consequence of this increased fecal bulk is the mechanical distension of the colonic walls. This physical stretching indirectly activates the local motor reflexes (peristalsis) of the large intestine. The physical changes thus facilitate the internal propulsion of colonic contents by leveraging the body's natural motor mechanism.

Dosage and Administration Information

How Forlax is Used: Official Administration Guidelines

This section details the usage patterns for Forlax (Macrogol 4000 without electrolytes), describing how the medicine is used in clinical practice.

Administration Scope

Feature	Description
Route of Administration	The approved method is oral use.
Labeled Dosing Regimen	The standard starting dose for adults and children aged 8 years and older is one sachet (10 g) per day. The dose may be adjusted from once every other day up to a maximum of two sachets (20 g) per day, depending on the response.
Frequency and Timing	The dose is preferably taken as a single dose in the morning. Intake should be separated by a minimum interval of two hours from other oral medications.
Preparation Requirements	The powder must be dissolved completely in 50 mL to 125 mL of water immediately before ingestion.
Missed Dose Rule	If a dose is forgotten, the instruction is to skip the forgotten dose and take the next dose at the usual time; double dosing is not recommended.

Labeled Course Duration and Use

Forlax is intended as a temporary measure and its use is subject to specific time limits.

Adults: The need for continued treatment requires reassessment after three months.
Children (aged 8 years and older): The duration of treatment should not exceed three months, as long-term data in this population are limited.

The protocol defines a single-dose, orally administered regimen with an adjustable daily dose, which is intended to be used temporarily as an adjunct to dietary measures. The need for treatment is subject to periodic review.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Forlax (Macrogol 4000)

The evidence base for Macrogol 4000 (the active substance in Forlax) includes Randomized Controlled Trials (RCTs) and Systematic Reviews that combine data from multiple studies. These studies were used in research exploring how symptoms change over time in adults and children with chronic functional constipation, a condition marked by functional limitations.

Research examined outcomes related to physical discomfort. The main changes measured during the study period included the frequency of spontaneous bowel movements and patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies where groups receiving Macrogol 4000 showed measurements related to these functional outcomes across short-term study intervals. Comparative studies also monitored outcomes when Macrogol 4000 was used alongside other treatments like lactulose, and data show patterns related to non-inferiority or similarity when comparing the two treatments.

Evidence for Use in Faecal Impaction

Research has also explored the use of Macrogol 4000 in protocols designed to evaluate outcomes related to faecal impaction, a condition associated with acute or disruptive episodes. This research has primarily involved controlled trials in the pediatric population. The studies monitored the measured rate of faecal mass clearance over defined, short time intervals. Findings indicate that groups using the Macrogol 4000 protocols reported measurements consistent with the predefined disimpaction outcome within the study period.

Research Gaps and Uncertainties

Despite the existing evidence structure for short-term use, certain gaps remain. The question of long-term effects is not fully resolved by prospective, blinded studies extending beyond one year, indicating that data for multi-year use are limited. Comparative evidence is also lacking against several other therapeutic approaches used for constipation, and subgroup findings are uncertain for several specific patient groups, such as pregnant women or those with rare comorbidities. Data for these groups remain insufficient.

Key Studies & References

How should Forlax be stored and disposed of?

How to Store and Dispose of Forlax

Storage Requirements

The powder for oral solution must be stored at or below 30 °C to maintain its quality. Beyond this temperature requirement, the regulatory label states there are no special storage precautions for the unopened sachets. A mandatory safety requirement is to keep this medicine out of the sight and reach of children at all times.

Condition	Requirement
Maximum Temperature	Store at or below 30 °C
Prepared Solution	For single use only; discard any unused solution
Unused Product	Do not use after the stated expiry date

Disposal Instructions

To protect the environment, official guidance specifies that medicines must not be disposed of in household waste or wastewater. Instead, consumers are directed to ask their pharmacist for advice on how to properly discard any expired or unused sachets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.